NCT07387926
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07387926
Title Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | child
Covered Countries NLD | ISR | FRA | AUS

Facility Status City State Zip Country Details
Novartis Investigative Site RECRUITING Sydney New South Wales 2031 Australia Details
Novartis Investigative Site RECRUITING Brisbane Queensland 4101 Australia Details
Novartis Investigative Site RECRUITING Melbourne Victoria 3004 Australia Details
Novartis Investigative Site RECRUITING Marseille 13885 France Details
Novartis Investigative Site RECRUITING Ramat Gan 5265601 Israel Details
Novartis Investigative Site RECRUITING Utrecht 3584 CS Netherlands Details
Novartis Investigative Site RECRUITING Seoul 03080 South Korea Details
Novartis Investigative Site RECRUITING Seoul 06591 South Korea Details
Novartis Investigative Site RECRUITING Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field